曲安奈德辅助23G微创玻璃体切割治疗增生性糖尿病视网膜病变#br#

doi:10.16260/j.cnki.1009-2188.2018.04.017

下载:

PDF (0KB)
输出: BibTeX | EndNote (RIS)

摘要［摘要］目的探讨23G微创玻璃体切割联合球内及后Tenon 囊下应用曲安奈德治疗增生性糖尿病视网膜病变(proliferative diabetic retinopathy, PDR)的安全性和有效性。方法选择行23G玻璃体切割手术治疗的PDR患者86例（95只眼）进行回顾性研究。按治疗方式分为两组：联合药物治疗组40例（48眼），行标准三切口玻璃体切割术, 术中球内注入曲安奈德8 mg行玻璃体染色并切割吸出, 术毕后Tenon 囊下注射曲安奈德30 mg；单纯手术治疗组46例（47眼），单纯行玻璃体切割手术，未注射曲安奈德。比较两组术后矫正视力及眼压情况，黄斑中心凹厚度（central macular thickness, CMT）变化及前房炎症反应情况。结果所有患者随访6个月～2年，平均（1.31±0.63）年。组内比较，两组治疗后各时间点最佳矫正视力（BCVA）、 CMT值均较术前改善（P均<0.05）；组间比较，术后1月、 3月、 6月联合药物治疗组BCVA、 CMT均优于单纯手术治疗组，差异均有统计学意义（P均<0.05）。两组患者眼压稳定，各时间点组内和组间比较均无统计学差异(P均＞0.05)。术后联合药物治疗组前房炎症反应较单纯手术治疗组轻，差异具有统计学意义(P<0.05)。手术后3～5 d，前房反应逐渐消失，所有病例未发生术后感染。结论23G微创玻璃体切割联合曲安奈德术中玻璃体染色及术毕后Tenon囊下注射治疗增生性糖尿病视网膜病变有效安全，能减轻黄斑水肿，改善视功能。

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周林
	李芳芳

关键词: 玻璃体切割术增生性糖尿病视网膜病变曲安奈德玻璃体染色后Tenon囊下注射

Abstract: Abstract:ObjectiveTo study the safety and efficacy of 23gauge miniinvasive vitrectomy combined with posterior subTenoncapsule injection of triamcinolone acetonide in treating proliferative diabetic retinopathy (PDR).MethodsA total of 86 PDR patients with 95 eyes underwent 23G vitrectomy were analyzed retrospectively. According to therapeutic method, they were divided into two groups: 40 cases of 48 eyes were treated by pars plana vitrectomy combined with injection of triamcinolone acetonide (TA) as the combined group, and 8 mg of TA was injected into the eyes for dying of vitreous during the operations and 30 mg of TA was injected in the posterior subTenoncapsule. 46 cases of 47 eyes were performed direct vitrectomy as pure surgery group. The best corrected visual acuity(BCVA), intraocular pressure (IOP), changes of central macular thickness(CMT), and inflammation reaction of anterior chamber were compared between the two groups．ResultsAll cases were followed up for 6 months to 2 years with an average of 1.31±0.63 years. The BCVA and CMT of the both groups were improved after treatment than those before the operation (P<0.05). Both BCVA and CMT were better in the combined group than those in the pure surgery group at 1, 3 and 6 months after the operation, and the differences were statistical (P<0.05)．The IOP was stable in both groups, and there was no
statistic difference at different time points in both groups and between the two groups (P>0.05). The inflammation reaction of anterior chamber in combined group was less than that in the pure surgery group(P<0.05)．
Conclusion23gauge miniinvasive vitrectomy combined with posterior subTenoncapsule injection of TA can reduce macular edema and improve visual acuity, and it is safe and effective for PDR.

Key words: vitrectomy proliferative diabetic retinopathy triamcinolone acetonide(TA) dyeing of vitreous posterior subTenoncapsule injection

出版日期: 2018-08-26 发布日期: 2018-10-23 期的出版日期: 2018-08-26

ZTFLH:
	R774.1

通讯作者: 周林，男，40岁，江苏省淮安市第二人民医院徐州医科大学附属淮安医院眼科副主任医师。

作者简介: 周林，男，40岁，江苏省淮安市第二人民医院徐州医科大学附属淮安医院眼科副主任医师。

引用本文:

周林, 李芳芳. 曲安奈德辅助23G微创玻璃体切割治疗增生性糖尿病视网膜病变#br#[J]. 中国现代手术学杂志, 2018, 22(4): 306-310.
ZHOU Lin, LI Fangfang. 23Gauge Miniinvasive Vitrectomy Combined with Adjunctive Triamcinolone Acetonide for Proliferative Diabetic Retinopathy#br#. Chinese Journal of Modern Operative Surgery, 2018, 22(4): 306-310.

链接本文:

http://www.surgerychina.com/CN/10.16260/j.cnki.1009-2188.2018.04.017 或 http://www.surgerychina.com/CN/Y2018/V22/I4/306